title: Prioritizing genomic applications for action by level of evidence: a horizon-scanning method.
abstract: As evidence accumulates on the use of genomic tests and other health-related applications of genomic technologies, decision makers may increasingly seek support in identifying which applications have sufficiently robust evidence to suggest they might be considered for action. As an interim working process to provide such support, we developed a horizon-scanning method that assigns genomic applications to tiers defined by availability of synthesized evidence. We illustrate an application of the method to pharmacogenomics tests.
authors.affiliation: Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
authors.forename: W D
authors.initials: WD
authors.lastname: Dotson
authors.affiliation: 1] Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA [2] McKing Consulting Corporation, Atlanta, Georgia, USA.
authors.forename: M P
authors.initials: MP
authors.lastname: Douglas
authors.affiliation: Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
authors.forename: K
authors.initials: K
authors.lastname: Kolor
authors.affiliation: 1] Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA [2] McKing Consulting Corporation, Atlanta, Georgia, USA.
authors.forename: A C
authors.initials: AC
authors.lastname: Stewart
authors.affiliation: Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
authors.forename: M S
authors.initials: MS
authors.lastname: Bowen
authors.affiliation: 1] Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA [2] McKing Consulting Corporation, Atlanta, Georgia, USA.
authors.forename: M
authors.initials: M
authors.lastname: Gwinn
authors.affiliation: 1] Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA [2] Cadence Group, Atlanta, Georgia, USA.
authors.forename: A
authors.initials: A
authors.lastname: Wulf
authors.affiliation: 1] Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA [2] McKing Consulting Corporation, Atlanta, Georgia, USA.
authors.forename: H M
authors.initials: HM
authors.lastname: Anders
authors.affiliation: Epidemiology and Genomics Research Program, National Cancer Institute, Bethesda, Maryland, USA.
authors.forename: C Q
authors.initials: CQ
authors.lastname: Chang
authors.affiliation: 1] Epidemiology and Genomics Research Program, National Cancer Institute, Bethesda, Maryland, USA [2] Kelly Services, Troy, Michigan, USA.
authors.forename: M
authors.initials: M
authors.lastname: Clyne
authors.affiliation: Epidemiology and Genomics Research Program, National Cancer Institute, Bethesda, Maryland, USA.
authors.forename: T K
authors.initials: TK
authors.lastname: Lam
authors.affiliation: Epidemiology and Genomics Research Program, National Cancer Institute, Bethesda, Maryland, USA.
authors.forename: S D
authors.initials: SD
authors.lastname: Schully
authors.affiliation: Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
authors.forename: M
authors.initials: M
authors.lastname: Marrone
authors.affiliation: Maine Dartmouth Family Medicine Residency Program, Augusta, Maine, USA.
authors.forename: W G
authors.initials: WG
authors.lastname: Feero
authors.affiliation: 1] Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA [2] Epidemiology and Genomics Research Program, National Cancer Institute, Bethesda, Maryland, USA.
authors.forename: M J
authors.initials: MJ
authors.lastname: Khoury
mesh_terms: D003657:Decision Making; D005820:Genetic Testing / Q000379:methods; D023281:Genomics; D016045:Human Genome Project; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods*